CTRI/2020/08/027043
Not yet recruiting
Phase 1
A Phase 1 clinical trial of intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with novel COVID-19 virus pneumonia.
eurogen Brain and Spine Institute0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Sponsor
- eurogen Brain and Spine Institute
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients admitted with RT\-PCR confirmed COVID\-19 illness.
- •Age: 18\-65 years without any uncontrolled comorbidities like hypertension, diabetes, renal failure, etc
- •Written informed consent
- •Has any of the two
- •PaO2/ FiO2: 200\-300
- •Respiratory Rate \> 24/min and SaO2 \<\= 93% on room air
Exclusion Criteria
- •Pregnant women
- •Breastfeeding women
- •Critically ill patients:
- •P/F ratio \< 200 (ARDS )
- •Shock (Requiring Vasopressor to maintain a MAP \>\= 65mmHg or MAP below 65\)
- •Patients with other severe co\-morbidities like cancer, chronic renal, chronic liver failure and chronic cardiac failure. This will not include diabetes, hypertension, etc
- •Participating in any other clinical trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
A Phase-I clinical study of intravenous AntiPlatelet, AntiCoagulant (APAC) in healthy subjects.CTRI/2023/04/051500Cadila Pharmaceutical Limited
Active, not recruiting
Phase 1
Trial to test the safety, half-life, and antiviral efficacy of a new drug (human antibody) called DZIF-10c (administered intravenously) in healthy volunteers and SARS-CoV-2-infected participantsSARS-CoV-2 infection (only mild to moderate disease)MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-003503-34-DEniversity of Cologne69
Completed
Not Applicable
Phase1 clinical study of a single intravenous dose of TRM-1106 in healthy Japanese adult meJPRN-UMIN000005914Terumo Corporation30
Unknown
Phase 3
Phase III Clinical Study of Intravenous Administration of S-021812 in Pediatric Patients with Influenza Virus InfectioInfluenza virus infectionJPRN-jRCT2080220845SHIONOGI & CO., LTD.100
Completed
Phase 2
Evaluating effect of intravenous midazolam on duration of spinal anesthesiaSpinal Anesthesia.Spinal anesthetics causing adverse effects in therapeutic useE938.7IRCT2014090716415N5Deputy of Research and technology of Isfahan University of Medical Sciences36